Replies to post #650660 on NorthWest Biotherapeutics Inc (NWBO)

[pgsd]

I also found it interesting that he also does not disclose he is a 'Founding Scientific Advisory Board member' of Alpheus Medical (along with Dr Roger Stupp)

Alpheus Medical
@alpheusmedical
[b"]Excited to announce our Phase 1 #glioblastoma #clinicaltrial for non-invasive #sonodynamictherapy is now enrolling. We also received #FDA Orphan Drug and Fast Track designations"

Learn how we aim to beat #braincancer.
https://rb.gy/dcuowd
#GBM #BTSM

Excited to announce our Phase 1 #glioblastoma #clinicaltrial for non-invasive #sonodynamictherapy is now enrolling. We also received #FDA Orphan Drug and Fast Track designations.

Learn how we aim to beat #braincancer. https://t.co/Af7YFzZwLV#GBM #BTSM

— Alpheus Medical (@alpheusmedical) July 13, 2022

Alpheus Medical Announces Formation of World-Class Scientific Advisory Board (SAB) to Support Development of Novel Treatment for Brain Cancer

Founding Scientific Advisory Board members include:

Dr. Roger Stupp – Dr. Stupp is the Paul C. Bucy Professor of Neurological Surgery and Professor of Neurology and Medicine (Hematology/Oncology) at Northwestern University Feinberg School of Medicine in Chicago. He is also the Chief of Neuro-Oncology in the Department of Neurology, and Co-Director of the Northwestern Medicine Lou and Jean Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center at Northwestern Memorial Hospital.

Dr. David Reardon – Dr. Reardon is Professor of Medicine at Harvard Medical School and currently serves as Clinical Director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute.

https://www.alpheusmedical.com/formation-of-scientific-advisory-board/

I am sure he is being well financially compensated for his work, seems suspicious that he discloses plenty of other conflicts of interest but not this one ?

Also, all four authors of the nwbo hit piece also author this other competing treatment.

Article
Open access
Published: 18 October 2023
Clinical trial links oncolytic immunoactivation to survival in glioblastoma
Alexander L. Ling, Isaac H. Solomon, Ana Montalvo Landivar, Hiroshi Nakashima, Jared K. Woods, Andres Santos, Nafisa Masud, Geoffrey Fell, Xiaokui Mo, Ayse S. Yilmaz, James Grant, Abigail Zhang, Joshua D. Bernstock, Erickson Torio, Hirotaka Ito, Junfeng Liu, Naoyuki Shono, Michal O. Nowicki, Daniel Triggs, Patrick Halloran, Raziye Piranlioglu, Himanshu Soni, Brittany Stopa, Wenya Linda Bi, Pierpaolo Peruzzi, Ethan Chen, Seth W. Malinowski, Michael C. Prabhu, Yu Zeng, Anne Carlisle, Scott J. Rodig, Patrick Y. Wen, Eudocia Quant Lee, Lakshmi Nayak, Ugonma Chukwueke, L. Nicolas Gonzalez Castro, Sydney D. Dumont, Tracy Batchelor, Kara Kittelberger, Ekaterina Tikhonova, Natalia Miheecheva, Dmitry Tabakov, Nara Shin, Alisa Gorbacheva, Artemy Shumskiy, Felix Frenkel, Estuardo Aguilar-Cordova, Laura K. Aguilar, David Krisky, James Wechuck, Andrea Manzanera, Chris Matheny, Paul P. Tak, Francesca Barone, Daniel Kovarsky, Itay Tirosh, Mario L. Suvà, Kai W. Wucherpfennig, Keith Ligon, David A. Reardon & E. Antonio Chiocca

https://www.nature.com/articles/s41586-023-06623-2

https://www.alpheusmedical.com/formation-of-scientific-advisory-board/